Case Based Panel Discussion - 2019 ALK Positive, Progression after Success on ALK Inhibitor

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.

Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. In this video series, the doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. This next panel discussion is regarding progression after success on an ALK inhibitor. Do you continue the ALK inhibitor when transitioning to a chemo based treatment?

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Related Content

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.

2025 Rare Cancers Patient Education Library

Video

In these videos, Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment. To watch the complete playlist, click here.